Evaluating Indivior Pharmaceuticals (NasdaqGS:INDV) After New ASAM 2026 Data On Sublocade Effectiveness

Indivior Pharmaceuticals (INDV) drew fresh investor attention after presenting new real world data at the ASAM 2026 Annual Conference in San Diego on its monthly extended release buprenorphine treatment, SUBLOCADE, for opioid use disorder.

See our latest analysis for Indivior Pharmaceuticals.

Those ASAM data arrive at a time when Indivior Pharmaceuticals’ share price has shown an 18.43% 1 month share price return but remains slightly weaker year to date, while a very large 1 year total shareholder return suggests momentum has been building over a longer horizon.

If you are tracking treatments for complex conditions like opioid use disorder, it can also be useful to widen your search across related opportunities using our healthcare focused 32 healthcare AI stocks.

With Indivior Pharmaceuticals trading at US$34.31, at a sizeable discount to a US$48.17 analyst price target and with a high value score of 5, is the recent momentum an entry point or is the market already pricing in future growth?

Most Popular Narrative: 9.4% Undervalued

Indivior Pharmaceuticals’ most followed narrative points to a fair value of $37.86 per share against the last close of $34.31. This frames the recent price strength within a modest undervaluation story driven by earnings expectations rather than short term sentiment.

The multiyear Indivior Action Agenda, including at least $150 million in annual operating expense savings and a capped 2026 operating budget of $450 million, is intended to materially lower the cost base and support the translation of revenue growth into earnings and cash flow expansion.

Read the complete narrative.

Curious what kind of earnings ramp and margin profile underpin that fair value, and how much profit multiple compression the narrative bakes in over time.

Result: Fair Value of $37.86 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, the thesis could shift if long acting injectables gain much higher OUD penetration, or if cost savings and SUBLOCADE traction lift margins beyond current analyst assumptions.

Find out about the key risks to this Indivior Pharmaceuticals narrative.

Another View: Earnings Multiple Sends A Different Signal

While the AI narrative and fair value point to a 9.4% undervaluation, the current P/E of 19.9x tells a more cautious story. It is higher than the US Pharmaceuticals average of 15.9x, yet close to an estimated fair ratio of 20.5x, which limits the margin of safety and raises the question of how much upside is really left.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals on value, growth, and sentiment, it makes sense to move quickly, examine the data yourself, and decide what really matters for you as an investor by weighing the 4 key rewards and 3 important warning signs.

Looking for more investment ideas?

If Indivior Pharmaceuticals is on your radar, do not stop there. Widening your watchlist with other high quality ideas can help you spot opportunities earlier.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com